AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Charcot-Marie-Tooth Disease

Recent research efforts aimed at curing Charcot-Marie-Tooth Disease.

Last updated

Charcot-Marie-Tooth Disease

Overview

Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that damage the peripheral nerves—the nerves connecting the brain and spinal cord to muscles and sensory organs. It usually causes slowly progressive weakness and muscle wasting in the feet and lower legs, foot drop, balance problems, high-arched feet or hammertoes, and reduced sensation; hand weakness can develop later. Symptoms often begin in childhood, adolescence, or early adulthood, but onset and severity vary substantially by genetic subtype. Most people have a normal life expectancy and remain ambulant, although disability can become substantial. GeneReviews CMT overview (ncbi.nlm.nih.gov)

CMT is not one disease with one cause: pathogenic variants in many genes can impair either myelin, the insulating coating around nerves, or axons, the long nerve fibers themselves. Current care is supportive rather than curative and typically includes physical and occupational therapy, exercise and stretching tailored to the individual, ankle-foot orthoses and other assistive devices, orthopedic surgery when needed, pain management, and genetic counseling. MedlinePlus Genetics CMT fact sheet NINDS CMT information (medlineplus.gov)

Scope of Recent Research (2020–present)

Research since 2020 has become more genetically targeted, with especially intensive work on CMT1A caused by excess PMP22, CMT2A caused by dominant MFN2 variants, CMTX1 caused by GJB1 variants, CMT4C caused by loss of SH3TC2, and CMT-SORD caused by deficient sorbitol dehydrogenase. The field now includes gene silencing, gene replacement, genome editing, metabolic small molecules, and treatments intended to improve muscle function regardless of subtype; however, the most root-cause-directed approaches remain preclinical, and no FDA-approved therapy has yet been shown to cure or durably halt CMT. Clinical-trials landscape analysis NMD Pharma Phase 2a update (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

For CMT1A, the central therapeutic idea is to reduce PMP22 expression toward its normal level without lowering it too far. In a major preclinical study, an adeno-associated virus serotype 9 (AAV9) vector carrying an artificial microRNA reduced PMP22/Pmp22 in Schwann cells—the cells that make peripheral-nerve myelin—and improved motor measures, nerve conduction, and pathology in both early- and later-treated CMT1A mice. A separate 2021 study used squalenoyl small-interfering-RNA nanoparticles to lower Pmp22 and improve neuropathy in CMT1A mouse models, supporting a potentially repeat-dose, nonviral alternative. AAV9 microRNA silencing in CMT1A mice PMP22 siRNA nanoparticles in CMT1A mice (pubmed.ncbi.nlm.nih.gov)

Genome editing is an even more direct but earlier-stage CMT1A strategy. Investigators used an AAV2-delivered small Cas9 enzyme and guide RNA to remove a portion of the duplicated PMP22 region in patient-derived induced pluripotent stem cell (iPSC) models. The intervention lowered PMP22 messenger RNA and protein toward normal, reduced cell death, and improved myelination in derived Schwann-cell cultures; importantly, the study was not a human trial and emphasized the need for rigorous testing for unintended DNA edits. AAV-mediated PMP22 editing in patient-derived cells (pubmed.ncbi.nlm.nih.gov)

Gene replacement is advancing for recessive or loss-of-function subtypes, where supplying a working gene may be conceptually more straightforward. In CMTX1 mice, intrathecal AAV9 delivery of GJB1 under a Schwann-cell-directed promoter improved motor performance, nerve conduction, myelination, inflammation, and blood biomarkers even when given after disease onset. Similarly, AAV9-mediated delivery of SH3TC2 improved motor, electrophysiological, and myelin outcomes in both early- and later-treated CMT4C mice; a 2026 dose-ranging study reported therapeutic benefit and no observed neural or peripheral-organ toxicity in its mouse experiments. GJB1 replacement in CMTX1 mice SH3TC2 replacement in CMT4C mice CMT4C dose-escalation preclinical study (pubmed.ncbi.nlm.nih.gov)

For CMT2A, researchers are pursuing ways to overcome the harmful effects of dominant MFN2 variants on mitochondrial movement and nerve energy supply. A 2023 proof-of-concept study combined RNA interference to suppress endogenous MFN2 with replacement by an RNAi-resistant normal copy, correcting mitochondrial distribution and abnormal mitochondrial recycling in patient-derived motor neurons and demonstrating vector delivery in a mouse model. More recently, AAV9-mediated expression of normal MFN2 restored endoplasmic-reticulum–mitochondria contacts and preserved neuromuscular-junction integrity and motor function in CMT2A mice, including after symptoms had begun. Combined RNAi and MFN2 replacement MFN2 gene therapy in CMT2A models (pubmed.ncbi.nlm.nih.gov)

Small molecules remain important because they can be given orally and may be easier to scale than individualized genetic medicines. Govorestat is an aldose reductase inhibitor designed for CMT-SORD, in which sorbitol accumulates because of SORD deficiency; it aims to prevent production of the toxic metabolite upstream. Other approaches seek to improve function rather than correct the causal variant: ignaseclant, formerly NMD670, inhibits the skeletal-muscle chloride channel ClC-1 to increase muscle responsiveness, while Actio Biosciences’ ABS-0871 inhibits overactive TRPV4 channels in the rare dominant subtype CMT2C. INSPIRE govorestat trial record Ignaseclant Phase 2a update ABS-0871 program (clinicaltrials.gov)

Clinical Trials and Experimental Approaches

The most advanced recent CMT1A medicine, PXT3003, is an oral combination of baclofen, naltrexone, and D-sorbitol intended to reduce disease-related PMP22 overexpression. In a published 323-participant Phase 3 study, the high-dose group showed a statistically significant improvement in the Overall Neuropathy Limitations Scale relative to placebo, but unexpected crystal formation in the high-dose formulation caused substantial discontinuation and complicated interpretation. A later 176-participant pivotal Phase 3 study, PREMIER, was completed in March 2024; the sponsor reported that its primary endpoint was confounded by unexpected improvement in the placebo group, and subsequent analyses did not establish a clear path to approval. Published PXT3003 Phase 3 trial PREMIER trial record Sponsor’s PREMIER analysis update (pubmed.ncbi.nlm.nih.gov)

Govorestat’s randomized Phase 2/3 INSPIRE trial in CMT-SORD has completed its placebo-controlled portion and transitioned participants to open-label treatment. Sponsor-reported analyses presented in 2025 included 12-month clinical data and additional 18- and 24-month analyses, but the full results have not yet been published in a peer-reviewed journal; a separate confirmatory study is registered to assess longer-term functional and patient-reported outcomes. INSPIRE trial record Govorestat INSPIRE presentation update Confirmatory govorestat study (clinicaltrials.gov)

In broader CMT1 and CMT2 populations, NMD Pharma’s randomized, double-blind Phase 2a SYNAPSE-CMT study enrolled 81 adults and tested 21 days of oral ignaseclant. The study did not meet its prespecified primary endpoint, the six-minute walk test, but the company reported improvements on several secondary measures of strength, function, and patient-reported outcomes, with no serious adverse events reported; these findings require peer-reviewed publication and confirmation in a longer study. ENCell also completed a nine-participant, dose-escalation Phase 1 study of umbilical-cord-derived mesenchymal stromal cells, EN001, in CMT1A, but the registry lists no posted results. SYNAPSE-CMT trial record Ignaseclant topline results EN001 Phase 1 trial record (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers use genetically engineered rodents, patient-derived iPSCs differentiated into motor neurons or Schwann cells, and neuron–Schwann-cell co-cultures to determine whether an intervention restores myelination, axonal transport, mitochondrial health, nerve conduction, and motor function. AAV vectors are being optimized for delivery into peripheral nerves through spinal-fluid injection and for cell-selective expression using promoters active in Schwann cells; RNA nanoparticles, antisense oligonucleotides, and gene-editing systems are being developed to overcome the additional challenge of reaching peripheral nerves safely and efficiently. CMT1A genome-editing study CMT4C AAV9 gene-replacement study CMT gene-therapy progress review (pubmed.ncbi.nlm.nih.gov)

The field is also improving the ability to detect meaningful change in a slowly progressive disease. Outcome platforms now combine clinical scales such as the CMT Functional Outcome Measure and CMT Health Index with walking, strength, nerve-conduction, wearable-sensor, and quantitative magnetic-resonance-imaging measures. In CMT1A, calf-muscle fat fraction measured by quantitative MRI changed over 12 months and predicted clinical change over longer follow-up, supporting its use as a bridging biomarker in therapeutic trials. Quantitative MRI longitudinal CMT1A study CMTA wearable-sensor program (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Important academic and clinical contributors include the Cyprus Institute of Neurology and Genetics, which has led Schwann-cell-targeted GJB1 and SH3TC2 AAV work; French and Italian groups developing PMP22 silencing/editing and MFN2 therapies; and multicenter clinical networks in the United States and Europe running CMT natural-history studies and trials. Industry programs include Applied Therapeutics’ govorestat, NMD Pharma’s ignaseclant, Actio Biosciences’ ABS-0871, and companies pursuing RNA and AAV platforms for CMT subtypes. GJB1 AAV9 study MFN2 gene-therapy study Actio CMT2C program (pubmed.ncbi.nlm.nih.gov)

Patient organizations provide unusually important translational support in this rare disease. The Charcot-Marie-Tooth Association reported $4.8 million in research investment in 2022, including $1.25 million across 12 CMT1A initiatives and additional preclinical support from its STAR Alliance partners. The CMT Research Foundation generally offers awards of roughly $100,000–$200,000 per year and reported approximately $2.66 million in future commitments for research and development projects in its 2025 audited statements. The Muscular Dystrophy Association reported more than $44 million invested in CMT research by the end of 2024, including a $300,000 infrastructure grant for standardized CMT clinical-evaluator training. CMTA 2022 research portfolio CMTRF funding program CMTRF 2025 audited statements MDA CMT research update (cmtausa.org)

Strengths, Limitations, and Challenges

The strongest recent advance is the transition from broadly symptomatic care toward therapies matched to disease mechanism: lowering excess PMP22 in CMT1A, replacing missing genes in recessive demyelinating subtypes, and correcting mitochondrial dysfunction in CMT2A. Animal and patient-cell experiments show that pathology can improve even after symptoms emerge, which is encouraging for real-world treatment. The emergence of better functional scales and quantitative MRI also makes it more feasible to measure whether a therapy changes disease trajectory rather than merely producing short-term symptomatic effects. AAV9 PMP22-silencing study CMT2A MFN2 gene therapy CMT1A MRI biomarker study (pubmed.ncbi.nlm.nih.gov)

The obstacles are considerable. CMT encompasses many genes and mechanisms, so a treatment for one subtype may be ineffective or harmful in another; for example, reducing PMP22 could be appropriate in CMT1A but not in disorders caused by insufficient PMP22. AAV-based treatments must reach enough long peripheral nerves and the correct cell type, avoid immune toxicity, provide an appropriate dose for years, and be manufactured affordably. Permanent genome editing adds concerns about off-target edits, while slow and variable progression makes clinical trials vulnerable to insensitive endpoints and placebo-group changes, as illustrated by the later PXT3003 study and the missed primary endpoint in SYNAPSE-CMT. PMP22 editing study PREMIER PXT3003 update Ignaseclant Phase 2a update (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of September 11, 2026, a universal cure for CMT is not close, but subtype-specific disease modification is more plausible than it was in 2020. The most important near-term milestones are peer-reviewed and regulatory-quality results from govorestat in CMT-SORD; replication and longer-duration testing of ignaseclant’s functional signals; clinical entry of PMP22-lowering therapies; and toxicology, biodistribution, and manufacturing packages that can move AAV gene-replacement programs for CMTX1, CMT4C, and CMT2A from animals to first-in-human trials. A true cure will probably require early genetic diagnosis, a therapy precisely matched to the causal gene and mechanism, and evidence that treatment preserves or restores long-term nerve function—not simply short-term performance. CMT clinical-trials assessment CMT4C translational gene-therapy study Govorestat confirmatory trial (pubmed.ncbi.nlm.nih.gov)

References

Don't see your disease? Request a report